Eccrine squamous syringometaplasia (ESS) has been associated with a characteristic clinical eruption in patients receiving chemotherapy. It has been suggested as a diagnostic clue in the diagnosis of chemotherapy-induced reactions vs acute graft-vs-host disease, as well as other drug reactions. We identified 10 cases of ESS in patients in whom a distinctive clinical eruption developed during or after a pretransplantation conditioning regimen with high-dose chemotherapy. A complete clinical and histologic evaluation was performed in all patients.
All patients developed erythematous and edematous plaques or confluent erythematous macular areas in the axillae and/or groin, with painful areas of well-defined erythema and edema on palms and/or soles in 5 patients. Some discrete papular lesions on the trunk or extremities could also be observed in most patients. The histologic hallmark of the eruption was ESS, with a variable degree of cornification and apoptosis. A vacuolar interface dermatitis and a variable degree of cellular atypica were also consistent findings.
Chemotherapy-induced ESS may be associated with a distinctive clinical eruption and should be considered in the differential diagnosis of erythematous eruptions during or after a pretransplantation conditioning regimen with high-dose chemotherapy.Arch Dermatol. 1997;133:873-878
Valks R, Fraga J, Porras-Luque J, Figuera A, Garcia-Diéz A, Fernández-Herrera J. Chemotherapy-Induced Eccrine Squamous Syringometaplasia: A Distinctive Eruption in Patients Receiving Hematopoietic Progenitor Cells. Arch Dermatol. 1997;133(7):873–878. doi:10.1001/archderm.1997.03890430089012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: